证券代码：301281 证券简称：科源制药 公告编号：2025-035 山东科源制药股份有限公司 关于《收购报告书摘要》的更正公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 山东科源制药股份有限公司于 2025 年 4 月 21 日披露了力诺投资控股集团有 限公司（以下简称"力诺投资"）及其一致行动人力诺集团股份有限公司（以下 简称"力诺集团"）出具的《山东科源制药股份有限公司收购报告书摘要》（以下 简称"原《收购报告书摘要》"），现相关信息披露义务人对原《收购报告书摘要》 的部分内容进行了更正，具体如下： 原《收购报告书摘要》"第一节 收购人及一致行动人介绍"之"四、收购人 及一致行动人从事的主要业务及最近三年的简要财务状况"之"（一）收购人" 之"2、最近三年的简要财务状况"相关内容： 力诺投资最近三年经审计的主要财务数据如下： 单位：万元 | 项目 | 2024 年末 | 2023 年末 | 2022 年末 | | --- | --- | --- | --- | | 总资产 | 1,137,430.15 | 1,106,984.15 | 952,9 ...

山东科源制药股份有限公司 收购报告书摘要（修订稿） 上市公司名称：山东科源制药股份有限公司 股票上市地点：深圳证券交易所 股票简称：科源制药 股票代码：301281 收购人名称：力诺投资控股集团有限公司 住所：中国（山东）自由贸易试验区济南片区经十东路 30766 号力诺科技 园 通讯地址：中国（山东）自由贸易试验区济南片区经十东路 30766 号 一致行动人名称：力诺集团股份有限公司 住所：中国（山东）自由贸易试验区济南片区经十东路 30766 号 通讯地址：中国（山东）自由贸易试验区济南片区经十东路 30766 号 签署日期：二〇二五年四月 收购人及一致行动人声明 本声明所述的词语或简称与本报告书摘要"释义"部分所定义的词语或简称 具有相同的含义。 一、本报告书摘要依据《中华人民共和国公司法》《中华人民共和国证券法》 《上市公司收购管理办法》《公开发行证券的公司信息披露内容与格式准则第 16 号——上市公司收购报告书》等相关法律、法规和规范性文件编制。 二、依据《中华人民共和国证券法》《上市公司收购管理办法》《公开发行证 券的公司信息披露内容与格式准则第 16 号——上市公司收购报告书》的规定， 本报告书 ...

Financial Performance - The company's revenue for Q1 2025 was ¥111,204,722.41, a decrease of 23.98% compared to ¥146,276,963.82 in the same period last year[5]. - Net profit attributable to shareholders increased by 7.25% to ¥23,084,866.50 from ¥21,523,763.06 year-on-year[5]. - Basic and diluted earnings per share rose by 7.24% to ¥0.2132 from ¥0.1988 in the previous year[5]. - Total operating revenue for Q1 2025 was CNY 111,204,722.41, a decrease of 24% compared to CNY 146,276,963.82 in the previous period[22]. - The net profit for the current period is 23,067,656.48, an increase of 7.2% compared to 21,523,763.06 in the previous period[23]. - The basic and diluted earnings per share for the current period are both 0.2132, up from 0.1988 in the previous period, reflecting a growth of 2.2%[23]. - The company reported a total profit of 23,647,716.46, slightly up from 23,229,047.36 in the previous period[23]. Cash Flow and Liquidity - The net cash flow from operating activities improved by 66.35%, reaching -¥552,148.66 compared to -¥1,640,883.14 in Q1 2024[5]. - Cash and cash equivalents decreased by 110.28% to -¥21,484,583.39, primarily due to the maturity of financial products[10]. - The cash and cash equivalents at the end of the period stand at 70,257,798.52, down from 568,547,454.88 at the end of the previous period[27]. - Total cash inflow from investment activities is 179,091,865.86, significantly down from 3,527,905,218.34 in the previous period[27]. - The net cash flow from investment activities is -36,794,402.27, compared to a positive flow of 209,416,222.37 in the previous period[27]. Assets and Liabilities - Total assets at the end of Q1 2025 were ¥1,576,012,493.61, reflecting a 1.52% increase from ¥1,552,474,271.14 at the end of the previous year[5]. - Non-current assets totaled CNY 895,845,377.25, up from CNY 861,739,402.58, marking an increase of about 4%[19]. - The total number of common shareholders at the end of the reporting period is 12,047[12]. - The company reported a decrease in total liabilities to CNY 192,768,042.27 from CNY 192,870,734.45, a reduction of about 0.05%[20]. - Short-term borrowings increased to ¥3,478,384.98, marking a 100% rise as a result of additional bank loans[9]. Shareholder Information - The largest shareholder, Linuo Investment Holding Group Co., Ltd., holds 34.39% of shares, totaling 37,240,000 shares, with 27,290,000 shares pledged[12]. - The second-largest shareholder, Wenze Hong, owns 7.76% of shares, amounting to 8,400,000 shares[12]. - The company has a total of 39,438,000 restricted shares, with no shares released during the reporting period[15]. - The company’s major shareholders include several state-owned and non-state-owned entities, indicating a diverse ownership structure[12]. - The company plans to maintain its current shareholder structure until the scheduled release of restricted shares in 2026[15]. - The total number of preferred shareholders at the end of the reporting period is zero, indicating no preferred shares issued[14]. Operational Performance - The company experienced a 36.74% decrease in operating costs, amounting to ¥54,145,854.92, attributed to a reduction in the quantity of products sold[9]. - Total operating costs for the same period were CNY 93,014,492.94, down 25% from CNY 124,459,548.73[22]. - The total operating expenses amount to 81,083,486.09, down from 89,961,054.86 in the previous period, indicating a reduction in costs[26]. - The company reported a significant increase in prepayments by 140.78%, totaling ¥6,795,685.39 due to increased procurement payments[9]. - Non-operating income surged to ¥4,000,321.41, a 100% increase due to additional non-recurring government subsidies received[9]. Market and Strategy - The company has not disclosed any new strategies or market expansions during this reporting period[16]. - The company has not reported any changes in the participation of major shareholders in margin trading activities[13]. - The company’s financial report indicates a stable shareholder base with no significant changes in the top 10 shareholders[12].

自2024年9月"并购六条"发布以来，A股市场医药行业并购重组活跃度持续提升，华润三九 （000999）、千金药业（600479）、圣湘生物等企业相继发布收购公告。 同时，近期全国多地政府相继出台政策，鼓励医药行业并购重组壮大发展，并提出医药产业基金的相关 规划。在更高层面，国务院国资委党委近日在《民主与法制》周刊发表署名文章中提出，对于生物医药 等产业基础比较薄弱的领域，鼓励国有企业运用并购重组、股权投资、产业基金等多种方式，加快形成 产业影响力。 上市公司并购提速 创道投资咨询合伙人步日欣表示，生物医药产业的投资周期一般较长，从研发到上市需要经历多个阶 段，是典型的"大长金"行业，即风险大、周期长、烧钱，所以生物医药的属性也决定了在目前环境下需 要通过并购重组来做大做强。 今年3月底，天士力（600535）连发数则公告，宣布已正式迎来华润三九的入主。此次交易历时约半 年，成为国内医药行业一项重要的"A收A"并购案例。 具体而言，华润三九以逾62亿元的总价，从天士力原控股股东天士力集团及其一致行动人手中协议受让 4.18亿股股份，占天士力总股本的28%，成为天士力的控股股东。华润三九认为收购有利于实现中药产 ...

Core Viewpoint - Koyuan Pharmaceutical is progressing with the acquisition of Shandong Hongjitang Pharmaceutical Group Co., Ltd., aiming to purchase 99.42% of its shares for approximately 3.581 billion yuan, which is expected to enhance the company's performance despite recent declines in its own financials [1][3]. Group 1: Transaction Details - The transaction involves issuing shares to 38 counterparties, including Lino Investment and Lino Group, to acquire 99.42% of Hongjitang's shares, with a total transaction price of approximately 3.581 billion yuan [2][3]. - Koyuan Pharmaceutical plans to raise up to 700 million yuan through a private placement to specific investors, which will not exceed 30% of the company's total share capital post-transaction [2][3]. - The acquisition will extend Koyuan's business into traditional Chinese medicine and health products, allowing for operational synergies and cost reductions [3]. Group 2: Financial Impact - Post-transaction, Koyuan's projected revenue for 2024 is 1.745 billion yuan, representing a 276.34% increase, while the attributable net profit is expected to be approximately 168 million yuan, a 177.86% increase compared to pre-transaction figures [4]. - The valuation of Hongjitang shows a high appraisal increment of 60.54%, with the net asset value assessed at 2.243 billion yuan and a market valuation of 3.602 billion yuan [5][6]. Group 3: Risks and Challenges - Hongjitang's production capacity utilization has declined significantly, with key products like Ejiao and Musk Ketone showing reduced utilization rates in 2024 compared to 2023 [8]. - If the low capacity utilization persists, it may lead to increased depreciation and amortization costs, potentially impacting Koyuan's net profits [9]. - Koyuan has reported a decline in its own net profit for the second consecutive year, with a 21.54% decrease in 2024 [9].

Group 1 - The company plans to issue shares to acquire 99.42% equity of Hongjitang from 38 trading parties, including Linuo Investment Holding Group Co., Ltd. and Linuo Group Co., Ltd. [1] - The company intends to raise no more than 700 million yuan through a share issuance to no more than 35 specific investors as supporting funds [1] - The target company's main business includes the research, production, and sales of traditional Chinese medicine and health products, as well as muscone [1]

中信建投证券股份有限公司 关于本次交易符合 《关于加强证券公司在投资银行类业务中聘请第三方等廉洁从业风 险防控的意见》 的相关规定之核查意见的核查意见 经核查，在本次交易中，上市公司分别聘请了中信建投证券股份有限公司、北 京世辉律师事务所、天健会计师事务所（特殊普通合伙）、中水致远资产评估有限 公司作为本次交易的独立财务顾问、法律顾问、审计机构和评估机构。上述中介机 构均为本次交易依法需聘请的证券服务机构，聘请行为合法合规。 中信建投证券股份有限公司（以下简称"中信建投"或"独立财务顾问"）作为科源 制药本次交易的独立财务顾问，按照《关于加强证券公司在投资银行类业务中聘请 第三方等廉洁从业风险防控的意见》（〔2018〕22号）的规定，就本次交易直接或 间接有偿聘请第三方机构或个人（以下简称"第三方"）的行为核查如下： 一、独立财务顾问不存在直接或间接有偿聘请第三方的行为 经核查，本次交易中，独立财务顾问不存在直接或间接有偿聘请第三方的行为， 符合《关于加强证券公司在投资银行类业务中聘请第三方等廉洁从业风险防控的意 见》的相关规定。 二、科源制药除依法需聘请的中介机构外不存在直接或间接有偿聘请其他第三 方的行为 ...

山东科源制药股份有限公司 发行股份购买资产 并募集配套资金暨关联交易报告书 （草案）摘要 | 项目 | 交易对方 | | --- | --- | | 发行股份购买资产 | 力诺投资、力诺集团等38名交易对方 | | 募集配套资金 | 不超过35名特定投资者 | 独立财务顾问 股票代码：301281 股票简称：科源制药 上市地点：深圳证券交易所 二〇二五年四月 声明 一、上市公司声明 本公司及全体董事、监事、高级管理人员已就在本次重组过程中所提供资料 真实性、准确性和完整性出具如下声明与承诺： "1、本公司/本人向参与本次交易的中介机构所提供的本次交易相关的资料 均为真实、准确、完整的原始书面资料或副本资料及信息，副本资料或者复印件 与其原始资料或原件一致；所有文件的签字与印章皆为真实的，不存在任何虚假 记载、误导性陈述或者重大遗漏，并对所提供信息的真实性、准确性和完整性承 担法律责任；如因提供的信息存在虚假记载、误导性陈述或者重大遗漏，给投资 者造成损失的，本公司/本人将依法承担个别及连带的法律责任。 2、本公司/本人保证为本次交易所出具的说明及确认均为真实、准确和完整 的，不存在任何虚假记载、误导性陈述或者 ...

德恒上海律师事务所 关于力诺投资控股集团有限公司 上海市虹口区东大名路 501 号上海白玉兰广场办公楼 23 层 电话：021-55989888 传真：021-55989898 邮编：200080 | 释义 4 | | --- | | 正文 5 | | 一、收购人及其一致行动人的主体资格 5 | | 二、本次收购的基本情况 7 | | 三、本次收购是否属于《收购管理办法》规定的可免于发出要约的情形 8 | | 四、本次收购涉及的法定程序 10 | | 五、本次收购的法律障碍 11 | | 六、本次收购有关的信息披露 11 | | 七、结论意见 12 | 德恒上海律师事务所 关于力诺投资控股集团有限公司 及其一致行动人免于发出要约事宜的法律意见 德恒上海律师事务所 关于力诺投资控股集团有限公司 及其一致行动人免于发出要约事宜的 法律意见 及其一致行动人免于发出要约事宜的 法律意见 德恒 02F20250177-0001 号 致：力诺投资控股集团有限公司 根据本所与力诺投资控股集团有限公司（以下简称"力诺投资"或"收购人"） 签署的《专项法律服务协议》，本所接受力诺投资的委托，就力诺投资及其一致 行动人免于发出要 ...

本资产评估报告依据中国资产评估准则编制 山东科源制药股份有限公司拟发行股份购买资产 所涉及山东宏济堂制药集团股份有限公司 股东全部权益价值项目 资产评估报告 中水致远评报字[2025]第 010079 号 中水致远资产评估有限公司 二0二五年四月二十日 中国资产评估协会 资产评估业务报告备案回执 | 报告编码: | 1111020131202500107 | | --- | --- | | 合同编号: | ZSZY [2024]0822 | | 报告类型: | 法定评估业务资产评估报告 | | 报告文号: | 中水致远评报字[2025]第010079号 | | 报告名称; | 山东科源制药股份有限公司拟发行股份购头资产用涉及山东玄济 堂制药集团股份有限公司股东全部权益价值项目 | | 评估结论: | 3.601,544,100.00元 | | 评估报告日: | 2025年04月20日 | | 评估机构名称: | 中水致远资产评估有限公司 | | | 正式会员 编号:11080051 (资产评估师) 杨颖锋 | | 答名人员: | (资产评估师) 正式会员 编号: 11130008 李鹏举 | (可扫描二维码查 ...